Harvest One Cannabis (TSXV: HVT) announced this morning that it has received approval from Health Canada to import Satipharm’s GelPell CBD capsules for research and development purposes. Satipharm is a wholly owned subsidiary of Harvest One, which is currently based in Dublin, Ireland.
The import of Satipharm’s product will be conducted by Harvest one’s licensed producer United Greeneries. The importation will allow Harvest to conduct compliance testing on the product, with a path to commercialize the product within Canada next year. The medical capsules contain hemp-extracted full spectrum CBD, with technology that results in the CBD being released into the small intestine for maximum effect. The result is a bioavailability that is 3.5 times higher than standard oil.
Harvest one concurrently announced that Satipharm has also commenced sales in Argentina, with the first patients already receiving product. The firm has signed an agreement with Argentina-based FederalMed for the purpose of importing its products for sale in the region.
At Harvest One, we view the Satipharm CBD Gelpell® capsule as a key part of our health, wellness, and self-care strategy and are very excited to be taking the next step in bringing them to the Canadian market. With this import permit, Harvest One can continue the necessary preparations to bring this unique, effective product to Canada.
Grant Froese, Chief Executive Officer of Harvest One
Satipharm’s CBD capsule products have undergone clinical stage I and II trials, which have been published in two peer reviewed journals.
Harvest One closed yesterdays session at $0.30 on the TSX Venture.
Information for this analysis was found via Sedar and Harvest One Cannabis Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
